Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment

Immune checkpoint‐blocking antibodies have therapeutic activity against relapsed or progressive classic Hodgkin lymphoma (cHL), but Hodgkin Reed‐Sternberg cells can develop resistance to this therapy via multiple mechanisms. To improve the efficacy of immune checkpoint blockade, we need a more preci...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbone, Antonino, Gloghini, Annunziata, Pruneri, Giancarlo, Dolcetti, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558469/
https://www.ncbi.nlm.nih.gov/pubmed/31070022
http://dx.doi.org/10.1002/cam4.2168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558469/
https://www.ncbi.nlm.nih.gov/pubmed/31070022
http://dx.doi.org/10.1002/cam4.2168

Ejemplares similares